Back

Hybrid therapy with ablation + subcutaneous ICD for secondary prevention of sudden cardiac death in ischemic heart disease

7 April 2024 (08:30 - 15:00)
Organised by: Logo
Congress Presentation Part of: Ventricular tachycardia 2 Ablation of Ventricular Arrhythmias EHRA Premium Access EHRA 2024 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Philippe Maury

Rangueil Hospital of Toulouse, Toulouse (France)

8 More presentations in this session

Presentation thumbnail
Left ventricular assist device in the presence of subcutaneous implantable cardioverter defibrillator: data from a multicenter experience
Professor F. Migliore (Padova, IT)
Abstract Slides Video
Presentation thumbnail
Rhythm matters: sinus and pace rhythm map significantly differ in endo/epicardial 3D electroanatomic mapping
Mr E. Heil (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Automated template matching versus conventional pace-mapping during pvc ablation: results from a randomized controlled trial.
Professor D. Steven (Cologne, DE)
Abstract Slides Video
Presentation thumbnail
Effects of hemodynamic support on arrhythmia-free survival following catheter ablation of ventricular arrhythmias
Doctor D. Guckel (Bad Oeynhausen, DE)
Abstract Slides Video
Presentation thumbnail
Manifestation of conduction block zones by substrate mapping evaluated under multidirectional pacing during ventricular tachycardia ablation
Doctor M. Hachisuka (Tokyo, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Ventricular tachycardia 2

The Event

Event poster

EHRA 2024

7 April - 9 April 2024
You may be interested in
thumbnail
Congress Presentation
Ablation is alternative to ICD therapy post-myocardial infarction patients with haemodynamically well-tolerated sustained monomorphic VT and LVEF>40%: pro
thumbnail
Congress Presentation
Subcutaneous versus transvenous implantable cardioverter-defibrillator therapy: real world data from a Portuguese cohort
thumbnail
Congress Presentation
long term follow up of Implantable Cardioverter Defibrillators (ICD) in hypertrophic cardiomyopathy: is subcutaneous the way forward?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources